Information Journal Paper
APA:
Copy. (2020). Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas. FRONTIERS IN IMMUNOLOGY, 11(-), 1-12. SID. https://sid.ir/paper/974985/en
Vancouver:
Copy. Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas. FRONTIERS IN IMMUNOLOGY[Internet]. 2020;11(-):1-12. Available from: https://sid.ir/paper/974985/en
IEEE:
Copy, “Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas,” FRONTIERS IN IMMUNOLOGY, vol. 11, no. -, pp. 1–12, 2020, [Online]. Available: https://sid.ir/paper/974985/en